Variability in the extent of del(5q) and its clinical implication in myelodysplastic syndromes (MDS).

被引：0
|
作者：
Zemanova, Zuzana
Brezinova, Jana
Svobodova, Karla
Lhotska, Halka
Izakova, Silvia
Sarova, Iveta
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.e19025
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e19025
引用
收藏
页数：1
相关论文
共 50 条
  • [41] RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q)
    Schuler, E.
    Schemenau, J.
    Giagounidis, A.
    Haase, D.
    Bueshce, G.
    Platzbecker, U.
    Nolte, F.
    Goetze, K.
    Schlenk, R. F.
    Ganser, A.
    Letsch, A.
    Luebbert, M.
    Schafhausen, P.
    Bug, G.
    Germing, U.
    LEUKEMIA RESEARCH, 2015, 39 : S62 - S62
  • [42] Familial occurrence of myelodysplastic syndrome with del(5q)
    Volpicelli, Paola
    Latagliata, Roberto
    Carmosino, Ida
    Breccia, Massimo
    Vozella, Federico
    Mancini, Marco
    Cannella, Laura
    Alimena, Giuliana
    LEUKEMIA & LYMPHOMA, 2011, 52 (06) : 1143 - 1145
  • [43] FISH studies of monosomy 5 in myelodysplastic syndromes reveal structural aberrations similar to del(5q).
    Hast, R
    Jakovleva, K
    Arvidsson, I
    BLOOD, 1999, 94 (10) : 496A - 496A
  • [44] Familiar occurrence of myelodysplastic sydrome with del(5q)
    Napoleone, L.
    Latagliata, R.
    Breccia, M.
    Vozella, F.
    Carmosino, I.
    De Cuia, R.
    Mancini, M.
    Volpicelli, P.
    Stefanizzi, C.
    Cannella, L.
    Mercanti, C.
    Alimena, G.
    LEUKEMIA RESEARCH, 2009, 33 : S97 - S98
  • [45] Prevalence and Impact on Outcomes of Additional Karyotypic Abnormalities in Patients (Pts) with Myelodysplastic Syndromes (MDS) and Del(5q) from the MDS-003 and MDS-004 Studies
    Giagounidis, Aristoteles
    List, Alan F.
    Hellstroem-Lindberg, Eva
    Mufti, Ghulam J.
    Schlegelberger, Brigitte
    Morrill, John
    Wu, Chengqing
    Skikne, Barry S.
    Fenaux, Pierre
    Goehring, Gudrun
    BLOOD, 2015, 126 (23)
  • [46] Molecular pathogenesis of myelodysplastic syndromes with deletion 5q
    Lee, Jung-hoon
    List, Alan
    Sallman, David A.
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2019, 102 (03) : 203 - 209
  • [47] Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
  • [48] Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment
    Acha, Pamela
    Mallo, Mar
    Sole, Francesc
    CANCERS, 2022, 14 (22)
  • [49] A NOVEL PCR-BASED ASSAY FOR TARGETED QUANTIFICATION OF DEL(5Q) IN MYELODYSPLASTIC SYNDROMES
    Jann, J. C.
    Nowak, D.
    Nolte, F.
    Fey, S.
    Nowak, V.
    Oblaender, J.
    Pressler, J.
    Fabarius, A.
    Haferlach, C.
    Medyouf, H.
    Hofmann, W. K.
    Mossner, M.
    LEUKEMIA RESEARCH, 2015, 39 : S80 - S80
  • [50] Treatment of myelodysplastic syndromes with del 5q before the lenalidomide era:: The GFM experience.
    Kelaidi, Charikleia
    Park, Sophie
    Brechignac, Sabine
    Mannone, Lionel
    Vey, Norbert
    Dombret, Herve
    Aljassem, Lina
    Starnatoullas, Aspasia
    Ades, Lionel
    Giraudier, Setphane
    de Botton, Stephane
    Mahe, Beatrice
    Lepelley, Pascale
    Picard, Fracoise
    Leroux, Genevieve
    Daniel, Marie-Threrese
    Bouscary, Didier
    Dreyfus, Francois
    Fenaux, Pierre
    BLOOD, 2006, 108 (11) : 757A - 757A
12345